Track topics on Twitter Track topics that are important to you
DGAP-News: Evotec AG / Key word(s): Miscellaneous
- JOINT DRUG DISCOVERY PROJECTS COMBINE CENTOGENE'S PATIENT ACCESS AND BIOMARKER EXPERTISE WITH EVOTEC'S LEADING IPSC PLATFORM
Hamburg, Rostock, Germany, 27 August 2018:
Evotec and CENTOGENE initiated the collaboration to develop a strategic high-throughput platform for testing novel small molecules in rare hereditary metabolic diseases.
The collaboration brings together Evotec's leading induced pluripotent stem cell ("iPSC") platform and broad drug discovery capabilities with CENTOGENE's unique medical and genetic insights. In particular, detailed genotype-phenotype data enables rapid biomarker development using patient primary cells.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "The collaboration between Evotec and CENTOGENE is focused on developing iPSC-based patient-derived disease models and suitable biomarkers for rare genetic diseases. A perfect match between highly complementary platforms and companies with the potential to open a new chapter in the translatability of pre-clinical discovery efforts into clinic benefits."
"The identification and development of innovative small molecules to treat rare, hereditary conditions is particularly challenging because of the absence of adequate cellular models and the general lack of specific biomarkers to monitor the different diseases. With this innovative collaboration between Evotec and CENTOGENE, we can accelerate the development of new drugs. CENTOGENE is fully committed to explore any given opportunity to discover new ways of helping patients and their families, together with its partners", said Dr Arndt Rolfs, CEO of CENTOGENE.
No financial details were disclosed.
ABOUT EVOTEC AG
FORWARD LOOKING STATEMENTS
|Manfred Eigen Campus / Essener Bogen 7|
|Phone:||+49 (0)40 560 81-0|
|Fax:||+49 (0)40 560 81-222|
|Listed:||Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange|
|End of News||DGAP News Service|
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...